Fluorescence-Guided Operation in Recurrent Glioblastoma Multiforme Treated with Bevacizumab—Fluorescence of the Noncontrast Enhancing Tumor Tissue?

Abstract

The oral application of 5-aminolevulinic acid (ALA) leads to an accumulation of fluorescent porphyrins in malignant glioma tissue, which simplifies complete tumor resection. If pretreated with bevacizumab, a vascular endothelial growth factor (VEGF) antibody, these patients might not show a contrast enhancement on magnetic resonance imaging (MRI) despite tumor progression. As VEGF antibodies induce a normalization of the tumor vasculature, it is not known whether fluorescence-guided surgery is of any value in patients pretreated with this antibody. One might speculate that missing contrast enhancement on MRI could result in minor or missing fluorescence after the application of ALA. Attempting to give some answers, we report the case of a patient who underwent fluorescence-guided reoperation of recurrent glioblastoma multiforme pretreated with bevacizumab.

Keywords

bevacizumab - fluorescence-guided surgery - glioblastoma multiforme - 5-aminolevulinic acid

• References

• 1 Stupp R, Mason WP, van den Bent MJ , et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10) 987-996
• 2 Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7 (5) 392-401
• 3 Lacroix M, Abi-Said D, Fourney DR , et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95 (2) 190-198
• 4 Giese A, Bock HC, Kantelhardt SR, Rohde V. Risk management in the treatment of malignant gliomas with BCNU wafer implants. Cen Eur Neurosurg 2010; 71 (4) 199-206
• 5 Kreisl TN, Kim L, Moore K , et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27 (5) 740-745
• 6 Batchelor TT, Sorensen AG, di Tomaso E , et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11 (1) 83-95
• 7 Winkler F, Kozin SV, Tong RT , et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6 (6) 553-563
• 8 Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8 (7) 1277-1280
• 9 Wen PY, Macdonald DR, Reardon DA , et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28 (11) 1963-1972
• 10 Friedman HS, Prados MD, Wen PY , et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27 (28) 4733-4740
• 11 Norden AD, Young GS, Setayesh K , et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70 (10) 779-787
• 12 Vredenburgh JJ, Desjardins A, Herndon II JE , et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13 (4) 1253-1259
• 13 Wick A, Dörner N, Schäfer N , et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 2011; 69 (3) 586-592
• 14 Lai A, Tran A, Nghiemphu PL , et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011; 29 (2) 142-148
• 15 Chinot O, de La Motte Rouge T, Moore N , et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 2011; 28 (4) 334-340
• 16 RTOG. Phase III double-blind placebo-controlled trial of conventional concurrent chemoradiation and adjuvant temozolomide plus bevacizumab versus conventional concurrent chemoradiation and adjuvant temozolomide in patients with newly diagnosed glioblastoma. Available at: www.rtog.org/members/protocols/0825/0825.pdf
• 17 Iwamoto FM, Abrey LE, Beal K , et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009; 73 (15) 1200-1206
• 18 Zuniga RM, Torcuator R, Jain R , et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009; 91 (3) 329-336
• 19 Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307 (5706) 58-62
• 20 Maxwell PH, Dachs GU, Gleadle JM , et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1997; 94 (15) 8104-8109
• 21 Rubenstein JL, Kim J, Ozawa T , et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2 (4) 306-314
• 22 Nowosielski M, Recheis W, Goebel G , et al. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology 2011; 53 (4) 291-302
• 23 Jain R, Scarpace LM, Ellika S , et al. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol 2010; 96 (3) 423-431
• 24 Ellingson BM, Cloughesy TF, Lai A , et al. Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. J Neurooncol 2011; 105 (1) 91-101
• 25 Stummer W, Reulen HJ, Meinel T , et al; ALA-Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62 (3) 564-576 , discussion 564–576
• 26 Stummer W, Stocker S, Wagner S , et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 1998; 42 (3) 518-525 , discussion 525–526
• 27 Roberts DW, Valdés PA, Harris BT , et al. Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between δ-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. J Neurosurg 2011; 114 (3) 595-603
• 28 Nabavi A, Thurm H, Zountsas B , et al; 5-ALA Recurrent Glioma Study Group. Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study. Neurosurgery 2009; 65 (6) 1070-1076 , discussion 1076–1077
• 29 Junck L. Bevacizumab antiangiogenic therapy for glioblastoma. Neurology 2011; 76 (5) 414-415
• 30 Díez Valle R, Tejada Solis S, Idoate Gastearena MA, García de Eulate R, Domínguez Echávarri P, Aristu Mendiroz J. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J Neurooncol 2011; 102 (1) 105-113
• 31 Narayana A, Kunnakkat SD, Medabalmi P , et al. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys 2012; 82 (1) 77-82